Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Biological markers are measurable indicators that can be used
to predict the risk of disease, to enable the diagnosis of disease, effects of treatment and to modify pathological processes and improving treatment selection and to monitor the results of therapeutic interventions. Biomarkers can be a gene, gene product, protein encoded by gene, hormone or an enzyme.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging
Biomarkers plays a major role in Oncology that are used in clinical research for risk assessment, differential diagnosis, determining nature of tumors, for screening purpose, to determine prognosis and drug dose-response to treatment. Biomarkers can predict behavior of tumor (benign/malignant), drug resistance. Biomarkers can establish the accuracy of diagnosis, can be associated to other investigations to suspect the type of Cancer.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: American association for Cancer research, American Society of Clinical Oncology, BASO-the association for Cancer surgery, Cent Pour Sang La Vie, French National Cancer Institute.
Neurology deals with diagnosis and treatment of disease conditions of central and peripheral nervous system and is one of the typical disciplines where personalized medicine has becoming an important part of clinical trials. Different issues in neurology are to be discussed in relation to personalized medicine and diagnostic, prognostic and predictive blood biomarkers.
The role of biomarkers & personalized medicine in neuro-oncology is becoming extensively important. The actual state of knowledge in several domains of neurology (neuro-oncology, cerebrovascular, neurodegenerative, and demyelinating diseases) are to be discussed.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: American Neurological Association (ANA), North American Neuromodulation Society, European Academy of Neurology, American Board of Psychiatry and Neurology, ALS society of Canada, International society for oncology.
Cancer therapy is continues to evolve, with immune-oncology offering a new approach to treatment that holds significant promise. If cancer is detected, patients undergo a variety of tests of diagnosis, prognosis, and treatment decision-making. The need for multiple, diverse diagnostic approaches to guide treatment decision-making in oncology is not likely to change, and the emergence of groundbreaking immunotherapeutic drugs that work by stimulating the immune system to attack a tumour is only adding to the diagnostic complexity. Biomarker-based CDx are essential to guide treatment decisions and are a valuable tool to aid in patient selection for clinical testing of new I/O drugs.
Tissue-based biomarkers are proving to be invaluable for helping to stratify patients based on the immune context of a tumour and the patient-specific characteristics of the tumour microenvironment as well as interactions between tumour and immune cells and between a tumour and surrounding tissues. Tissue context biomarkers can capture this diversity and complexity, and biomarker-based CDx can drive individualized treatment decisions.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Association: International society for oncology, American association for cancer research, American Society of Clinical Oncology, BASO-the association for Cancer surgery, Cent Pour Sang La Vie, French National Cancer Institute.
ic or predictive types. Many of these biomarkers have been vigorously tested to assess their clinical utility across different patients with atherosclerotic CVD. The desirable characteristics of any cardiovascular biomarker includes measurement should be easy, preferably at point-of-care over a short period of time with adequate precision and accuracy. These biomarkers can reflect pathophysiologic process of cardiovascular diseases, and also may be able to give information about prognosis and assist guide clinical decision making without duplicating any information that is already available clinically.
Biomarkers evaluating prognostic outcomes should report discrimination, calibration and reclassification in patients by evaluating statistical models with and without the biomarker in order to demonstrate their added value over traditional and other commonly used biomarkers. Genetic biomarkers are at the forefront of being evaluated for added utility and they too need rigorous assessments to evaluate their relations with the CVD and for their added advantage over traditional risk factors. Utilizing biomarkers as surrogate end points for predictive and prognostic values in clinical trials will likely dictate our future of CVD treatment, and will also open up avenues to evaluate biomarkers as possible targets for drug delivery and development.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: Acute Cardiovascular Care Association, European Society of Cardiology, Cardiac Society of Australia, American Heart Association.
Recent research of Biotechnology and Genomics signifies the advancement of biomarkers to detect individual disease risk and enhance diagnostic classification to better inform personalized treatment. The identification and development of biomarkers for personalized, preventive and predictive medicine was a major impulse of Human Genome Project.
Biomarkers related to Genomics measure changes in the quantity or nature of nucleic acids . DNA-based biomarkers include copy number variation, mutations(including polymorphisms, somatic mutations, and other genetic variants), and epigenetic modifications. RNA expression-based biomarkers include quantification of mRNA, microRNA and long noncoding RNA expression.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations:The Genome consortium for active teaching, American Society for Human Genetics, American Society for Gene therapy, European Molecular Biology laboratory.
Serum consists of number of small sized peptides, as a result of various cellular activities, called as the serum proteome. Proteomics has been widely used to study wide range of medical field includes drug development and Biomarker discovery. By correlating with other advanced techniques in genomics and bioinformatics, proteomics has the extensive contribution to biomarker identification and to revolutionize drug development process.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: Protein research foundation, Proteome Society, Australasian Proteomics Society, European Molecular Biology laboratory.
Molecular Biomarkers are alteration expressions of structures of nucleic acids, proteins and proteoglycans Cancer diagnosis is currently undergoing a standard shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. Molecular alteration ranges from the DNA, RNA, microRNAs (miRNAs) and proteins. The miRNAs are recently discovered small non-coding endogenous single-stranded RNAs that critically regulates the development, invasion and metastasis of cancer. They are altered in cancers and have the potential to serve as diagnostic markers for cancer.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging
Transcriptomics referred to as gene expression profiling is the quantitative study of genes expressed in a biological state. Advanced technologies enables quantitative assessment of all expressed genes (transcriptome) in a given tissue. These advancements provide a powerful tool for understanding biological systems and for developing novel biomarkers. Transcriptomics has powerful impact on the field of cardiovascular biomarkers and several transcriptome biomarkers are accessible for clinical research. Transcriptomics have shown that aggregate measures comprised of multiple genes are also informative as biomarkers of complex disease.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging
Biomarkers are major tools in drug development and pharmaceutical research. Biomarkers have been recognized in making the drug development process to be more efficient and have become an essential part of Pharmacology and pharmaceutical research. Number of biomarkers are expected that will ultimately transition into the clinical laboratory.
Biomarkers demonstrate drug dose–response relationships between biomarker changes, onset of injury, and severity of injury that correspond to progression of the injury.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: International Pharmaceutical Federation, International Pharmaceutical Students Federation, Pharmaceutical Group of European Union (PGEU), Pharmaceutical Society of Australia.
The Biomarkers have incredible potential to affect rate of success of clinical trials and identify new drug targets and advance diagnostic assays for early detection of disease. Biomarker development originates in the drug discovery phase and leads to clinical validation stage. In the target, discovery and validation stage biomarkers are used to identify and justify targets for therapy.
Biomarkers should have consistent characteristics with an acceptable sensitivity and specificity representing a specific toxicity or therapeutic effect of the drug, a specific physiological response to a treatment, a pathological progression, or a physiological factor.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: International Pharmaceutical Federation, International Pharmaceutical Students Federation, Pharmaceutical Group of European Union (PGEU), Pharmaceutical Society of Australia.
Biomarkers used to detect the presence of a disease or condition and to identify individuals with subtype of disease. Diagnostic Biomarkers allows the development of screening programs of certain cancers (cellular and molecular pathology). Therapeutic biomarkers has involved in huge therapeutic range in treating cardiovascular, rare diseases, infectious diseases, inherited diseases.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging, International Pharmaceutical Federation, International Pharmaceutical Students Federation, Pharmaceutical Group of European Union (PGEU), Pharmaceutical Society of Australia.
Pharmacogenomics and Personalized medicine is an advanced practice of medicine that implies on individual’s genetic profile to guide decisions made to the diagnosis, prevention and treatment of particular diseases to the right patient at the right time giving right therapy. There are number of personalized medicines than before in clinical pipeline across many diseases. Pharmacogenomics & Personalized medicine is advanced through data from the Human Genome Project. Biomarkers plays an important role in making use of pharmacogenomics, pharmaco proteomics for development of personalized medicine.
Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK
Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
